Emmett L, Subramaniam S, Joshua A, Crumbaker M, et al. ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int 2021 May 24. doi: 10.1111/bju.15491.
PMID: 34028967